ES2104056T3 - Composiciones estables de porfimero sodico y metodos para su preparacion. - Google Patents

Composiciones estables de porfimero sodico y metodos para su preparacion.

Info

Publication number
ES2104056T3
ES2104056T3 ES93303290T ES93303290T ES2104056T3 ES 2104056 T3 ES2104056 T3 ES 2104056T3 ES 93303290 T ES93303290 T ES 93303290T ES 93303290 T ES93303290 T ES 93303290T ES 2104056 T3 ES2104056 T3 ES 2104056T3
Authority
ES
Spain
Prior art keywords
preparation
methods
composition
stable compositions
supplied
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93303290T
Other languages
English (en)
Inventor
Stephen L Clauss
Michael J Pastel
Rainer K Zawadzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novelion Therapeutics Inc
Original Assignee
Quadra Logic Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Technologies Inc filed Critical Quadra Logic Technologies Inc
Application granted granted Critical
Publication of ES2104056T3 publication Critical patent/ES2104056T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE SUMINISTRA UNA COMPOSICION DE SODIO ESTABLE EN SU ALMACENAMIENTO (ETER-ESTER DE POLIHEMATOPORFIRINA) UTIL EN LA TERAPIA FOTODINAMICA DEL CANCER U OTRAS ENFERMEDADES. LA COMPOSICION SE CARACTERIZA EN QUE EL PORCENTAJE DE OLIGOMEROS DE PORFIRINA UNIDO A ESTERES ES MENOR AL 10% DE LA COMPOSICION. TAMBIEN SE SUMINISTRAN PROCESOS MEJORADOS PARA PREPARAR TALES COMPOSICIONES EN DONDE LA HEMATOPORFIRINA ACETILADA SE TRATA CON ALCALI DURANTE UN TIEMPO SUFICIENTE Y UNA TEMPERATURA ADECUADA PARA REDUCIR LA CANTIDAD DE OLIGOMEROS DE PORFIRINA UNIDOS POR ENLACES DE ESTER A MENOS DEL 10% DE LA COMPOSICION.
ES93303290T 1992-04-27 1993-04-27 Composiciones estables de porfimero sodico y metodos para su preparacion. Expired - Lifetime ES2104056T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/873,860 US5244914A (en) 1992-04-27 1992-04-27 Stable porfimer sodium compositions and methods for their manufacture

Publications (1)

Publication Number Publication Date
ES2104056T3 true ES2104056T3 (es) 1997-10-01

Family

ID=25362473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93303290T Expired - Lifetime ES2104056T3 (es) 1992-04-27 1993-04-27 Composiciones estables de porfimero sodico y metodos para su preparacion.

Country Status (10)

Country Link
US (2) US5244914A (es)
EP (1) EP0568323B1 (es)
JP (1) JP2928047B2 (es)
KR (1) KR100221206B1 (es)
AT (1) ATE150968T1 (es)
CA (1) CA2094974C (es)
DE (1) DE69309340T2 (es)
DK (1) DK0568323T3 (es)
ES (1) ES2104056T3 (es)
GR (1) GR3023978T3 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5882328A (en) * 1995-01-13 1999-03-16 Qlt Phototherapeutics, Inc. Method to prevent transplant rejection
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
WO2007142132A1 (ja) * 2006-06-02 2007-12-13 Hamamatsu Foundation For Science And Technology Promotion ポルフィリン（ｙ）の多価金属化合物の新規製造方法
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8793075B2 (en) 2008-10-31 2014-07-29 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8551505B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8788211B2 (en) * 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050070B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111857A1 (en) 2008-10-31 2010-05-06 Boyden Edward S Compositions and methods for surface abrasion with frozen particles
US8721583B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US9060934B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8798932B2 (en) 2008-10-31 2014-08-05 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8545855B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
PH12012500928A1 (en) 2009-11-09 2012-11-26 Allergan Inc Compositions and methods for stimulating hair growth
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
CA3056396A1 (en) 2017-03-14 2018-09-20 Ohio State Innovation Foundation Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates
KR102182630B1 (ko) 2019-12-19 2020-11-24 김진왕 친환경 스마트 광감작제 및 이를 포함하는 광줄기세포 치료제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US4882234A (en) * 1986-11-12 1989-11-21 Healux, Inc. Storage-stable porphin compositions and a method for their manufacture
US4861876A (en) * 1986-11-26 1989-08-29 Wayne State University Hematoporphyrin derivative and method of preparation and purification
US5059619A (en) * 1989-06-14 1991-10-22 Quadra Logic Technologies, Inc. Stable freeze-dried polyhematoporphyrin ether/ester

Also Published As

Publication number Publication date
DK0568323T3 (da) 1997-07-07
CA2094974C (en) 1996-10-22
KR100221206B1 (ko) 1999-10-01
DE69309340T2 (de) 1997-07-17
ATE150968T1 (de) 1997-04-15
EP0568323A1 (en) 1993-11-03
JPH06220062A (ja) 1994-08-09
JP2928047B2 (ja) 1999-07-28
EP0568323B1 (en) 1997-04-02
US5244914A (en) 1993-09-14
GR3023978T3 (en) 1997-10-31
DE69309340D1 (de) 1997-05-07
CA2094974A1 (en) 1993-10-28
KR930021143A (ko) 1993-11-22
US5438071A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
ES2104056T3 (es) Composiciones estables de porfimero sodico y metodos para su preparacion.
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
BR8803709A (pt) Umectante para uma composicao de tratamento de pele e a respectiva composicao
EP0569773A3 (en) Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
GR3019315T3 (en) Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
ES2088655T3 (es) Esteres de l-carnitina y alcanoil l-carnitinas con acido glicolico o sus esteres y composiciones farmaceuticas que las contienen para tratar dermatosis.
ATE192647T1 (de) Medikamente auf der basis von docosahexaensäure, als plättchenaggregationshemmer und gegen cerebralen mangel an fettsäuren, und verfahren zur herstellung.
BR9402089A (pt) Composição para cuidado da pele e processo para melhorar as propriedades de irritação provocada por retinol
ES2117281T3 (es) Nuevos analogos de la vitamina d.
CA2196906A1 (en) Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
PT74928B (en) New anti-thromboticum based on polysachatides method for its preparation and pharmaceutical compositions
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
ATE172108T1 (de) Verwendung von diglycerinestern gegen unreine haut
DE3463728D1 (en) Sebum secretion accelerator
AR224877A1 (es) Nuevos 3,4,5-trihalofenol esteres de acidos carboxilicos alifaticos o aromaticos,composiciones antimicrobianas que contienen estos esteres y procedimiento para proteger material mediante tratamiento con dichos compuestos o composiciones
DE69322252D1 (de) Formulierung und verwendung von carotenoiden in der krebsbehandlung
AR015696A1 (es) Composicion y metodo para tratar la piel o el cabello humano
ES2062175T3 (es) Medicamentos y productos dieteticos con contenido de nuevos derivados de acilaminoacidos.
ES2035102T3 (es) Compuestos que contienen hierro biodisponible, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2093226T3 (es) Retinoides sustituidos con un ciclo ditiano y su empleo, procedimiento de preparacion de dichos compuestos, composiciones cosmetica y farmaceutica que los contienen y empleo terapeutico de esta ultima.
ES475083A1 (es) Procedimiento para la preparacion de esteres de aminoalcoho-les y derivados del acido 2-fenilpropionico.
MX9303242A (es) Compuestos de fosfonosulfonato novedosos, composiciones farmaceuticas y metodos para tratamiento de metabolismo anormal de calcio y fosfato.
ATE113291T1 (de) Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 568323

Country of ref document: ES